Loading clinical trials...
Loading clinical trials...
A Phase 2 Clinical Trial to Evaluate the Efficacy of Zanubrutinib Plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia
Conditions
Interventions
Zanubrutinib,Ixazomib and Dexamethasone
Locations
1
China
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China
Start Date
June 1, 2020
Primary Completion Date
December 6, 2022
Completion Date
December 6, 2022
Last Updated
February 11, 2026
NCT05006716
NCT01815749
NCT02362035
NCT01769222
NCT03187262
NCT02933320
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions